-
Join the ADA in New Orleans for the 2026 Scientific Sessions
Experts from across the globe will convene to share the latest cutting-edge advances in diabetes research, prevention, and care June 5–8 as part of an education program featuring 200 sessions across 25 topic areas.
-
Expand your network within the diabetes community
Attendees of the 2026 Scientific Sessions will have several opportunities to engage with other diabetes professionals, starting with Friday evening’s Networking Reception.
2025 Scientific Sessions Newsmakers
-
Specialists explain how to maximize impact of AI-enabled diabetes-related retinopathy screening
Roomasa Channa, MD, and other panelists detailed how diabetes-related retinopathy screening programs using artificial intelligence can be cost effective and help improve adherence to screening guidelines.
-
Experts debate relevance of bariatric surgery in the era of GLP-1 RAs
Ali Aminian, MD, and Neda Rasouli, MD, weighed how the efficacy of this pharmacotherapy for the treatment of obesity impacts the role of metabolic surgery for this patient population.
-
Panel shares ideas to augment traditional study approaches
Experts, including Deborah J. Wexler, MD, MSc, shared novel approaches to designing studies in diabetes health care. The importance of a collaborative approach among patients, care teams, and institutions was a common theme.
-
CATALYST shows mifepristone for hypercortisolism in type 2 diabetes reduces A1C, weight
Vivian Fonseca, MD, and other investigators explained the results of the largest prospective study to date of hypercortisolism in difficult-to-treat diabetes and pharmacotherapy of hypercortisolism.
-
Add-on therapy improves glycemic outcomes and weight loss in adults living with type 1 diabetes and obesity
Researchers, including Viral N. Shah, MD, shared findings from phase 2 of the ADJUST-T1D study for the first time at the Scientific Sessions in Chicago. Once-weekly semaglutide enhanced the efficacy of automated insulin delivery alone in meeting time-in-range and weight-reduction targets.
-
Experts contrast heart and kidney diseases in type 1 and type 2 diabetes
Robert H. Eckel, MD, Silvio Litovsky, MD, and Anand Srivastava, MD, MPH, explored differences between type 1 and type 2 diabetes in respect to cardiovascular and kidney complications, then interpreted what this means for future research and ongoing clinical care.